Sangwon Lee

Yale University

$1,966,950

Attributed

$1,966,950

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $844.3K · FY2022–25

$1M$750K$500K$250K$0

'22

'23

'24

'25

Funding mix

By agency

NIH$1,966,950 · 2

By mechanism

R01$1,505,804 · 1

R21$461,146 · 1

Top collaborators

No co-investigators on record.

Most similar at Yale University

Same institution · by research overlap

Others in their field

Other Rising Stars on “Novel Therapeutic Intervention”

Rebecca Montalvan · Westat, Inc.$86,600,000
Angee Greer · Ppd Development Lp$82,531,927
Cynthia M Visness · Rho Federal Systems Division, Inc.$14,006,776
Suma Babu · Massachusetts General Hospital$11,004,714
Sabrina Paganoni · Massachusetts General Hospital$11,004,714
Michael E. Roth · Public Health Institute$8,201,777

Research focus

Novel Therapeutic InterventionSpecificityInsightNovel StrategiesPathway InteractionsSignal TransductionFamily MemberInhibitorIn VitroMouse ModelNovel TherapeuticsPathogenicityEffective TherapyPublic HealthBindingAffectFibroblast Growth FactorFibroblast Growth Factor ReceptorsAffinityBiophysicsIn VivoMalignant NeoplasmsCellsUnited States

Grant awards (5)

Targeting Isoform-specific FGFR Signaling in Idiopathic Pulmonary Fibrosis$461,146

R21 · FY2025 · AG · contact PI

Therapeutic targeting of FGF19-driven cancers with FGF21 variants$383,156

R01 · FY2025 · CA · contact PI

Therapeutic targeting of FGF19-driven cancers with FGF21 variants$363,999

R01 · FY2024 · CA · contact PI

Therapeutic targeting of FGF19-driven cancers with FGF21 variants$375,493

R01 · FY2023 · CA · contact PI

Therapeutic targeting of FGF19-driven cancers with FGF21 variants$383,156

R01 · FY2022 · CA · contact PI